Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21070242 | 0.98 | MAPT (0.39) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25718956 | 0.98 | MAPT (0.39) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25581839 | 0.98 | MAPT (0.39) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7072100 | 0.95 | CPB2 (0.36) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25207445 | 0.91 | MAPT (0.40) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL26924302 | 0.91 | MAPT (0.40) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL25216274 | 0.91 | MAPT (0.40) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7073506 | 0.87 | HDAC6 (0.34) | CA14CPB2HDAC1HDAC2HDAC6 | |
| SCHEMBL21070332 | 0.85 | ALDH1A1 (0.38) | CA14MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL22777483 | 0.83 | ALDH1A1 (0.41) | CA14MAPTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| CN-114245797-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| CN-114245797-A | CGRP antagonist compounds | 赫普泰雅治疗有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | WYETH (US) | 2003-06-12 | — | — | US | disclosed |
| US-6429214-B1 | INHIBITORS OF BONE RESORPTION | WYETH | 2002-08-06 | — | — | US | disclosed |
| EP-1198231-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE(ALPHA)V(BETA)3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CA14 4647/4885MAPT 2614/4885CYP1A2 2339/4885 |
| US-20030109523-A1 | Bicyclic antagonists selective for the alphavbeta3 integrin | ITGAV, ITGB2, ITGB3 | CA14 3740/4885MAPT 4836/4885CYP1A2 2396/4885 |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | CALCRL, CALCR, OPRL1 | CA14 4647/4885MAPT 2614/4885CYP1A2 2339/4885 |
| US-12227521-B2 | CGRP antagonist compounds | CALCRL, CALCR, OPRL1 | CA14 4647/4885MAPT 2614/4885CYP1A2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.